December 8, 2009 – The first live U.K. cases involving Cappella’s self-expanding Sideguard Coronary Sidebranch Stent and delivery system were recently performed at PCI Live 2009 with the second case following immediately thereafter, off-camera.
Dr. Joseph D. Mills, consultant cardiologist at the Liverpool Heart and Chest Hospital, U.K., performed both procedures. “We see numerous bifurcation cases and are very pleased to see that there is now a dedicated and straightforward solution to treating complex bifurcation lesions,” Dr. Mills said. “As the first centre in the U.K. to use Sideguard, we are very satisfied with the results.”
Cappella recently added an additional size of 3.25 mm to their current portfolio of 2.5 and 2.75 mm stents. This now enables treatment of bifurcation lesions in lumen diameters from 2.25 to 3.25 mm and lesion lengths less than or equal to 7 mm.
The Sideguard focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. It allows the preferred stent of choice for the main vessel. The stent offers an optimal design specific to the anatomy of the sidebranch, combined with the qualities of nitinol.
For more information: www.cappella-med.com, http://multivu.prnewswire.com/mnr/cappella/41383/
October 16, 2024 
